ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
House of Representatives Committee Passes Bill to Stabilize Physician Reimbursement
On May 21, the House Ways and Means Committee passed H.R. 8163,…
PET Lauded as Powerful Diagnostic Tool During Congressional Hearing
“[Cardiac PET] gives us very good data, probably the most accurate, about…
ACR Wants Congress to Require AUC Consultation: A Prescriptive AUC Mandate Is Not the Answer!
On May 20, the American College of Radiology (ACR) CEO will testify…

